Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "strong-buy" rating in a research note issued to investors on Saturday.
Several other equities analysts have also recently weighed in on the company. Bank of America restated an "underperform" rating and set a $20.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, June 29th. Piper Sandler decreased their price objective on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a "neutral" rating on the stock in a report on Friday. Weiss Ratings reiterated a "sell (d+)" rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Barclays cut their target price on shares of Amphastar Pharmaceuticals from $23.00 to $20.00 and set an "equal weight" rating for the company in a report on Wednesday, June 3rd. Finally, Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Friday, May 8th. Six analysts have rated the stock with a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals presently has a consensus rating of "Reduce" and a consensus price target of $22.00.
View Our Latest Analysis on Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Stock Up 4.9%
AMPH opened at $20.78 on Friday. The company has a market capitalization of $916.19 million, a PE ratio of 12.30, a price-to-earnings-growth ratio of 4.18 and a beta of 0.89. The firm has a 50-day simple moving average of $19.66 and a two-hundred day simple moving average of $21.39. The company has a quick ratio of 2.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.79. Amphastar Pharmaceuticals has a 52 week low of $16.65 and a 52 week high of $31.26.
Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.29. The firm had revenue of $183.90 million for the quarter, compared to analysts' expectations of $179.92 million. Amphastar Pharmaceuticals had a return on equity of 14.92% and a net margin of 10.76%. Analysts forecast that Amphastar Pharmaceuticals will post 2.25 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Amphastar Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the stock. Quarry LP bought a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $32,000. Farther Finance Advisors LLC lifted its position in Amphastar Pharmaceuticals by 46.3% in the fourth quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company's stock worth $37,000 after buying an additional 437 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Amphastar Pharmaceuticals by 24.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company's stock worth $60,000 after buying an additional 435 shares during the period. TD Private Client Wealth LLC boosted its stake in Amphastar Pharmaceuticals by 410.1% during the fourth quarter. TD Private Client Wealth LLC now owns 2,418 shares of the company's stock worth $65,000 after buying an additional 1,944 shares during the period. Finally, Quadrant Capital Group LLC purchased a new position in Amphastar Pharmaceuticals during the third quarter worth $82,000. Hedge funds and other institutional investors own 65.09% of the company's stock.
Key Stories Impacting Amphastar Pharmaceuticals
Here are the key news stories impacting Amphastar Pharmaceuticals this week:
- Positive Sentiment: Amphastar reported second-quarter revenue of $183.9 million, exceeding analysts’ approximately $179.9 million estimate. Adjusted earnings were $0.91 per share, well above consensus estimates ranging from $0.62 to $0.66 and up from $0.85 a year earlier. GAAP net income totaled $30.3 million, or $0.67 per share, while adjusted net income was $40.8 million. Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
- Positive Sentiment: The earnings beat was broad enough to attract attention from analysts, with coverage highlighting stronger-than-expected revenue, EPS and other key quarterly metrics. The results provide a positive near-term catalyst for AMPH and help support its valuation despite the stock remaining below its 200-day moving average. Amphastar Pharmaceuticals Q2 Earnings and Revenues Top Estimates
- Neutral Sentiment: Wells Fargo raised its price target from $19 to $20 but maintained an “equal weight” rating. The revised target remains below the recent trading level, signaling limited perceived upside despite the earnings performance. Wells Fargo price-target update
- Negative Sentiment: Piper Sandler lowered its price target from $21 to $20 and assigned a “neutral” rating. The downgrade in target suggests analysts remain cautious about AMPH’s outlook and could temper the positive reaction to the quarterly beat. Piper Sandler price-target update
About Amphastar Pharmaceuticals
(
Get Free Report)
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company's manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.
Amphastar's portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
